Navigation Links
TopoTarget Successfully Buys Back Full Control of Belinostat
Date:4/22/2008

Target shares issued through a directed issue of shares and a commercial milestone payment of a total of USD 6 million (approximately DKK 28.3 million), which is defined as 10% of the first USD 60 million (approximately DKK 283.5 million) of belinostat sales or partnership revenues.

Belinostat is currently being tested in 18 clinical trials (10 sponsored by the NCI) to treat different types of cancer. Belinostat is safe and well-tolerated also when combined with chemotherapy, and has the unique flexibility of being administered both intravenously and orally in capsule form. This differentiates belinostat from its competitors. In 2007, the product was included in Windhover Information's top ten of the most interesting cancer products for partnering.

"TopoTarget will now push forward the development of belinostat to benefit cancer patients and will focus on bringing the drug to the market as soon as possible. Today's deal represents a great opportunity for TopoTarget and its shareholders by gaining sole ownership of belinostat. We can now pursue an initial registration in PTCL using our in house proven clinical and regulatory team and focus on pursuing a partnership with a large pharma which has the development and commercialisation muscle to exploit belinostat's blockbuster potential," said Peter Buhl Jensen, CEO of TopoTarget.

TopoTarget's belinostat strategy TopoTarget will now focus its resources on the development of belinostat, and the company has initiated a reorganisation to reflect this focus. In the second half of this year TopoTarget expects to launch the first registration trial in PTCL, a disease where no standard treatment is approved. TopoTarget is also pursuing a fast track status and an orphan drug status for this indication. With clinical trials commencing in the second half of 2008, TopoTarget believes a market approval could be obtained in 2010.

TopoTarget also expects to pursue a development programme in ovarian cancer
'/>"/>

SOURCE TopoTarget A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
2. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
3. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Life on Mars pregnancy test successfully launched
7. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. Citrate appears to control buckyball clumping but environmental concerns remain
10. Vela Laboratories Receives the GMP Certificate for Its Analytical and Quality Control Laboratories
11. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2008)...FirstCall/ -- Eli Lilly and,Company (NYSE: LLY ) ...ion,of SGX Pharmaceuticals, Inc. (Nasdaq: SGXP ),...n drug discovery and development in the area,of on...s Special,Stockholders Meeting, in which a majorit... agreement with Lilly. Under the agreement, Lilly ...
(Date:8/20/2008)... and Caregivers, Grassroots ...ewswire-USNewswire/ -- Inc. Magazine has,named Sen...an for,low-income seniors, the number one fastest-...rt of Inc.,s annual list of the country,s 500 fast...1,000 percent from 2004 to 2007., "This is a rewa...
(Date:8/20/2008)...ll/ -- CEL-SCI CORPORATION,(Amex: CVM ) reports f...ing,June 30, 2008., The Company,s loss from opera...76,679 versus a loss of $3,776,263 during the same...ns for the nine months ended June 30, 2008,was $7,...e nine months in,2007., The net loss per common s...
(Date:8/20/2008).../ -- Huifeng Bio-Pharmaceutical,Technology, Inc (O...producer of plant extracts and pharmaceutical raw ... and food production, today announced it will,be i... August 19-21 in Rio,de Janeiro, Brazil., "Unpara...volved in the,pharmaceutical raw materials industr...
Breaking Biology Technology:Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 2CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 3CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 4CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results 5Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil 2
...just for Midwestern technology job seekers. Its al...e concentrated so hard on job seekers here? Becaus...art of the reason. More than that, it,s because th...echnology job hunting. So many things to know. So ...e are so many ways to scotch your chances for your...
...ular entities approved by the federal Food and Dru...s are scrambling for ways to speed up the laboriou...about 18 years from the start of target discoveryi... wants to influenceto introduce a new drug to mark...maceutical companies and the research firms that c...
...eneration tech savvy leaders , ,The new Universit...e Life and Engineering Sciences (SMILES) MBA deg... housed in the University of Wisconsin-Madisons Ma... program aims to provide business expertise to stu... and engineering fields. , ,Students enroll in th...
...Network has received from NorthStar Economics an a...a primer for Wisconsin companies seeking informati...d Ward and his team have agreed to exclusively exc...ays forth and final installment is: , , Seed-Stag...e often comparatively modest capital amounts provi...
Other Biology Technology:Its Your Midwest Technology Wake, Stupid 2Its Your Midwest Technology Wake, Stupid 3Researchers Push for Faster Drug Development 2Researchers Push for Faster Drug Development 3UWs Tech Students Gain MBA Business Expertise 2UWs Tech Students Gain MBA Business Expertise 3Seed-Stage Venture Financing 2Seed-Stage Venture Financing 3Seed-Stage Venture Financing 4Seed-Stage Venture Financing 5
(Date:8/20/2008)...e (NHGRI), part of the National Institutes of Heal...rants to develop innovative sequencing technologie...erson,s DNA as a routine part of biomedical resear...sively sequence any person,s genome is the type of...lized medicine where healthcare providers can use ...
(Date:8/19/2008)...though the basic developmental lineage of pituitar...ociate specific changes in gene expression with ma... article on p. 546 of the September 2008 issue of...pproach of comparing the nuclear proteome of two g...ifferent stages of development. Their results demo...
(Date:8/19/2008)...ring bran flakes; it can also preserve important t...nstitute of Standards and Technology (NIST) have d...for evaluating the sugars pharmaceutical companies...m temperature. The group presented their findings*...eeting and Exposition. , Protein-based drugs suc...
(Date:8/19/2008)... received a $3.2 million grant from the National S...ical science and mathematical disciplines to stem ... the program can equip experts in fields such as c...and biomaterials to move stem-cell breakthroughs f...y viable therapies. , NSF awarded the five-year ...
Breaking Biology News(10 mins):NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 2NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 3NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 4NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 5September 2008 Biology of Reproduction highlights 2Candy-coating keeps proteins sweet 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3Dr William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 7798 1Dr William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 7798 2Dr William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 7798 3Green Tea Fruit Extracts Touted as Potential Cancer Fighters 7793 1Green Tea Fruit Extracts Touted as Potential Cancer Fighters 7793 2Green Tea Fruit Extracts Touted as Potential Cancer Fighters 7793 3JCI online early table of contents 3A Dec 6 2007 7791 1JCI online early table of contents 3A Dec 6 2007 7791 2JCI online early table of contents 3A Dec 6 2007 7791 3JCI online early table of contents 3A Dec 6 2007 7791 4JCI online early table of contents 3A Dec 6 2007 7791 5JCI online early table of contents 3A Dec 6 2007 7791 6JCI online early table of contents 3A Dec 6 2007 7791 7JCI online early table of contents 3A Dec 6 2007 7791 8JCI online early table of contents 3A Dec 6 2007 7791 9The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 1The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 2The Polls are Open 21 America Votes to Decide Which Hospital is the Most Deserving of Siemens Newest MRI Technology 7786 3
...an East Tennessee valley adjacent to the Oak Ridge...lex, toxic waste from weapons manufacturing at the...dwater that extends in radioactive plumes for mile... State University Associate Professor Joel Kostka ... clean up the mess. , During the course of a fo...
...rotect sensitive tissue throughout the body have a...ful medications away. To overcome this hurdle, Joh...noparticles with a chemical that helps them slip t...s with these coated particles, the researchers als...res than previously thought, providing a doorway t...
...may soon be able to eat prawns without the fear of...n a promising step towards removing from prawns th... resorting to genetic manipulation, reports Lisa R...of the SCI. , Li Zhenxing led the research at the ...treating prawns with a combination of heat and irr...
...rd University School of Medicine has helped confi...e that is ushering in the long-promised era of per...etic makeup. , The Stanford group was one of the f...test can identify patients who are at high risk of...fection. That means high-risk patients could be d...
Other Biology News:'Hidden-hero' microbes in soil, water may help naturally clean toxic sites 2Coated nanoparticles solve sticky drug-delivery problem 2Coated nanoparticles solve sticky drug-delivery problem 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
...n that has been shown to help maintain the integri...anscription, in vitro RNA transcription, and in v... binds RNases in a 1:1 ratio. It inhibits a broad ...B, RNase C, and human placental RNase. RNA Safe do...
FastStart High Fidelity PCR System, dNTPack (Not available in US) from Roche Applied Science
RNase Inhibitor (Ribonuclease inhibitor) is a 50 kDa recombinant enzyme used to inhibit RNase activity. It does not contain DNase or endonuclease activity. , Inhibits RNase activity, preventing degr
HEPA Filtered Single Chamber Water Jacketed Incubator, CO2/O2 IR, 115V, 50/60 Hz from Thermo Scientific
Biology Products: